Paradigm Biopharmaceutica (Australia) Today
| PAR Stock | 0.39 0.03 7.14% |
PerformanceWeak
| Odds Of DistressQuite High
|
Paradigm Biopharmaceutica is selling for under 0.39 as of the 25th of March 2025; that is 7.14 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.39. Paradigm Biopharmaceutica has more than 67 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 25th of December 2024 and ending today, the 25th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Paradigm Biopharmaceutica is entity of Australia. It is traded as Stock on AU exchange. The company has 389.43 M outstanding shares. More on Paradigm Biopharmaceuticals
Moving together with Paradigm Stock
Moving against Paradigm Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Paradigm Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Paradigm Biopharmaceutica's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Paradigm Biopharmaceutica or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | ||||
Paradigm Biopharmaceutica's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Paradigm Biopharmaceutica's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsParadigm Biopharmaceutica can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Paradigm Biopharmaceutica's financial leverage. It provides some insight into what part of Paradigm Biopharmaceutica's total assets is financed by creditors.
| |||||
Paradigm Biopharmaceuticals (PAR) is traded on Australian Securities Exchange in Australia and employs 11 people. Paradigm Biopharmaceutica is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 150.71 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Paradigm Biopharmaceutica's market, we take the total number of its shares issued and multiply it by Paradigm Biopharmaceutica's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Paradigm Biopharmaceutica operates under Biotechnology sector and is part of Health Care industry. The entity has 389.43 M outstanding shares.
Paradigm Biopharmaceutica generates negative cash flow from operations
Check Paradigm Biopharmaceutica Probability Of Bankruptcy
Ownership AllocationParadigm Biopharmaceutica owns a total of 389.43 Million outstanding shares. Paradigm Biopharmaceutica holds 12.3 pct. of its outstanding shares held by insiders and 15.69 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Paradigm Ownership Details
Paradigm Biopharmaceutica Risk Profiles
Although Paradigm Biopharmaceutica's alpha and beta are two of the key measurements used to evaluate Paradigm Biopharmaceutica's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 4.08 | |||
| Semi Deviation | 4.74 | |||
| Standard Deviation | 5.26 | |||
| Variance | 27.65 |
Paradigm Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Paradigm Biopharmaceutica without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run ETF Categories Now
ETF CategoriesList of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
| All Next | Launch Module |
Paradigm Biopharmaceutica Corporate Management
Elected by the shareholders, the Paradigm Biopharmaceutica's board of directors comprises two types of representatives: Paradigm Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Paradigm. The board's role is to monitor Paradigm Biopharmaceutica's management team and ensure that shareholders' interests are well served. Paradigm Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Paradigm Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ravi Krishnan | Chief Officer | Profile | |
| Michael Imperiale | Global MPS | Profile | |
| Justin Cahill | Chief Officer | Profile | |
| Mukesh Ahuja | Global OA | Profile |
Additional Tools for Paradigm Stock Analysis
When running Paradigm Biopharmaceutica's price analysis, check to measure Paradigm Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Paradigm Biopharmaceutica is operating at the current time. Most of Paradigm Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Paradigm Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Paradigm Biopharmaceutica's price. Additionally, you may evaluate how the addition of Paradigm Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.